drugset / Trial / NCT06037018
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, open-label, dose-escalation study to evaluate the safety, PK, PD and immunogenicity of CC312 following intravenous doses of CC312 in patients with relapsed and refractory (r/r) CD19 expressing B-cell non-Hodgkin lymphoma and B-cell lymphocytic leukemia.
Timeline
- Start
- 2023-08-07
- Primary completion
- 2026-03
- Completion
- 2026-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CC312 | Other / unclassified | 0.3 ug | Intravenous |
| Subject | CC312 | Other / unclassified | 0.6 ug | Intravenous |
| Subject | CC312 | Other / unclassified | 1.2 ug | Intravenous |
| Subject | CC312 | Other / unclassified | 2.4 ug | Intravenous |
| Subject | CC312 | Other / unclassified | 4.8 ug | Intravenous |
| Subject | CC312 | Other / unclassified | 9.6 ug | Intravenous |
| Subject | CC312 | Other / unclassified | 16 ug | Intravenous |
| Subject | CC312 | Other / unclassified | 24 ug | Intravenous |
| Subject | CC312 | Other / unclassified | 34 ug | Intravenous |
| Subject | CC312 | Other / unclassified | 45 ug | Intravenous |